A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Researchers from Guandong Pharmaceutical University reported on the synthesis and preclinical characterization of a series of novel long-acting peroxisome proliferator-activated receptor (PPAR) ...

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...

Quintuple agonists herald a new era in obesity care, unlocking the potential for powerful, sustained weight loss and improved ...

CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...

Reneo Pharmaceuticals, developing therapies for rare genetic mitochondrial diseases, has been added to the Russell 3000 index and raised around $55 million through a recent public offering. RPHM's ...

The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...